HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: jnumed.107.040097v1 48/6/1017    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nye, J. A. Articles by Votaw, J. R. Search for Related Content PubMed PubMed Citation Articles by Nye, J. A. Articles by Votaw, J. R.

Biodistribution and Radiation Dosimetry of the Synthetic Nonmetabolized Amino Acid Analogue Anti-¹⁸F-FACBC in Humans

Division of Nuclear Medicine, Department of Radiology, Emory University, Atlanta, Georgia

Correspondence: For correspondence or reprints contact: Jonathon A. Nye, PhD, Department of Radiology, Emory University, 1364 Clifton Rd., NE, Atlanta, GA 30030.E-mail: Jonathon.Nye{at}emoryhealthcare.org

The synthetic leucine amino acid analog anti-1-amino-3-¹⁸F-fluorocyclobutane-1-carboxylic acid (anti-¹⁸F-FACBC) is a recently developed ligand that permits the evaluation of the L-amino acid transport system. This study evaluated the whole-body radiation burden of anti-¹⁸F-FACBC in humans. Methods: Serial whole-body PET/CT scans of 6 healthy volunteers (3 male and 3 female) were acquired for 2 h after a bolus injection of anti-¹⁸F-FACBC (366 ± 51 MBq). Organ-specific time–activity curves were extracted from the reconstructed data and integrated to evaluate the individual organ residence times. A uniform activity distribution was assumed in the body organs with urine collection after the study. Estimates of radiation burden to the human body were calculated on the basis of the recommendations of the MIRD committee. The updated dynamic bladder model was used to calculate dose to the bladder wall. Results: All volunteers showed initially high uptake in the pancreas and liver, followed by rapid clearance. Skeletal muscle and bone marrow showed lower and prolonged uptake, with clearance dominated by the tracer half-life. The liver was the critical organ, with a mean absorbed dose of 52.2 µGy/MBq. The estimated effective dose was 14.1 µSv/MBq, representing less than 20% of the dose limit recommended by the Radioactive Drug Research Committee for a 370-MBq injection. Bladder excretion was low and initially observed 6 min after injection, well after peak tracer uptake in the body organs. Conclusion: The PET whole-body dosimetry estimates indicate that an approximately 370-MBq injection of anti-¹⁸F-FACBC yields good imaging and acceptable dosimetry. The nonmetabolized nature of this tracer is favorable for extraction of relevant physiologic parameters from kinetic models.

Key Words: anti-¹⁸F-FACBC • dosimetry • amino acid • PET

COPYRIGHT © 2007 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2007 48: 11a-12a. [Full Text]  

This article has been cited by other articles:

				M. P.S. Dunphy and J. S. Lewis Radiopharmaceuticals in Preclinical and Clinical Development for Monitoring of Therapy with PET J. Nucl. Med., May 1, 2009; 50(Suppl_1): 106S - 121S. [Abstract] [Full Text] [PDF]

				J.-M. Beauregard, E. Croteau, N. Ahmed, J. E. van Lier, and F. Benard Assessment of Human Biodistribution and Dosimetry of 4-Fluoro-11{beta}-Methoxy-16{alpha}-18F-Fluoroestradiol Using Serial Whole-Body PET/CT J. Nucl. Med., January 1, 2009; 50(1): 100 - 107. [Abstract] [Full Text] [PDF]

				K. Kaira, N. Oriuchi, Y. Otani, K. Shimizu, S. Tanaka, H. Imai, N. Yanagitani, N. Sunaga, T. Hisada, T. Ishizuka, et al. Fluorine-18-{alpha}-Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer: A Clinicopathologic Study Clin. Cancer Res., November 1, 2007; 13(21): 6369 - 6378. [Abstract] [Full Text] [PDF]